Physician profile
Richard John Oneill
NPI 1265570485
$1,411.26
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $379 · 2021: $329 · 2022: $291 · 2023: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $105.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $345.92 | 2019-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $239.42 | 2019-2023 | Mounjaro |
| Amarin Pharma, INC. | $206.46 | 2020-2021 | |
| Allergan, INC. | $74.82 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $69.44 | 2022 | |
| Pfizer INC. | $64.87 | 2019-2020 | |
| Abbvie INC. | $43.37 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $41.14 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $37.27 | 2020 | |
| Novartis Pharmaceuticals Corporation | $34.31 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $32.65 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.08 | 2020-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $31.35 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $24.52 | 2022 | |
| Merck Sharp & Dohme LLC | $22.71 | 2023 | Belsomra |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $18.67 | 2021 | |
| Daiichi Sankyo INC. | $18.49 | 2019 | |
| Mylan Specialty L.P. | $18.23 | 2021 | |
| Esperion Therapeutics, INC. | $15.71 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $14.99 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.60 | 2021 | |
| Boston Scientific Corporation | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Oneill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.